Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Thrombotic and bleeding complications in AL amyloidosis

Efstathios Kastritis • 16 Jun 2020
EHA 2020
Amyloidosis Rare Diseases

Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses thrombotic and bleeding complications in patients with amyloid light-chain (AL) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Efstathios Kastritis

Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis 0:52
Monitoring, diagnosing & managing cardiotoxicity in AL amyloidosis
Efstathios Kastritis • 29 May 2024
The outcomes of patients with AL amyloidosis and end-stage renal disease 1:44
The outcomes of patients with AL amyloidosis and end-stage renal disease
Efstathios Kastritis • 29 Jun 2024
Differentiating between amyloidosis and myeloma 1:22
Differentiating between amyloidosis and myeloma
Efstathios Kastritis • 29 May 2024

Related Videos

Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes 2:03
Molecular classification of Waldenström’s macroglobulinemia: the identification of two subtypes
Gareth Morgan • 7 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals